Cardiovascular and Renal Risks of Tacrolimus in Lupus Nephritis: A Long-Term Retrospective Cohort Study
- Glomerular Diseases: Clinical and Epidemiologic Studies
November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Trials
- van Schaik, Mieke, Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
- Bredewold, Edwin, Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
- Priester, Merel, Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
- Michels, Wieneke, Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
- Rabelink, Ton J., Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
- Rotmans, Joris I., Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
- Teng, Yoe Kie Onno, Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
Systemic lupus erythematosus is associated with an increased risk of cardiovascular disease. Tacrolimus is a calcineurin inhibitor that finds its origin in solid organ transplantation, but is also effectively used in lupus nephritis. In a transplant setting, tacrolimus is associated with an increased cardiovascular risk, including nephrotoxicity, hypertension, dyslipidemia and hyperglycemia. In lupus nephritis the use of tacrolimus is off-label, and since head-to-head comparisons and long-term evaluations are lacking, its safety profile is less well-defined. Our objective was to investigate the long-term effects of tacrolimus on cardiovascular and renal outcomes in lupus nephritis patients.
In a retrospective, single-center cohort study, all adult lupus nephritis patients treated in the Leiden University Medical Center between 2004 and 2023 were investigated and dichotomized based on the prescription of systemic tacrolimus. We evaluated the Framingham risk score and the occurrence of cardiovascular events, diabetes, dyslipidemia, and change in kidney function.
Of 223 patients that were enrolled in the study, 45 (20.2%) were ever prescribed tacrolimus. The remaining 178 patients had never been prescribed calcineurin inhibitors and were assigned to the control group. There was an equal incidence of cardiovascular events in both groups. The 10-year risk of coronary heart disease was significantly lower in the tacrolimus group, although this could largely be contributed to the age difference between the groups. Tacrolimus use was an independent predictor of eGFR decline, but this did not result in larger incidence of end-stage kidney disease during the follow-up period. There was no difference in the occurrence of diabetes or dyslipidemia between the groups, although there was a significant increase in HbA1c in the tacrolimus group.
Tacrolimus may have nephrotoxic and modest diabetogenic effects in lupus nephritis patients. Caution when prescribing tacrolimus and vigilance towards these possible side effects when continuing tacrolimus treatment as maintenance treatment is advised. However, further prospective studies in larger cohorts are necessary to confirm these findings and further assess the side-effects of tacrolimus in lupus nephritis patients.